[
  {
    "ts": null,
    "headline": "Pfizer Could Be The Turnaround Story In The Pharmaceutical Space",
    "summary": "Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.",
    "url": "https://finnhub.io/api/news?id=54c1d4f545964d3d8dc5420b9a717674da4e0cc1148d85422ddf7bc71ba31d77",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750895850,
      "headline": "Pfizer Could Be The Turnaround Story In The Pharmaceutical Space",
      "id": 135532900,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.",
      "url": "https://finnhub.io/api/news?id=54c1d4f545964d3d8dc5420b9a717674da4e0cc1148d85422ddf7bc71ba31d77"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Declares Third-Quarter 2025 Dividend",
    "summary": "NEW YORK, June 25, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer.",
    "url": "https://finnhub.io/api/news?id=d0bb0d7eb666335e58628cecff0b54ef6df7349066194cabdb76cadd128ed2e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750887000,
      "headline": "Pfizer Declares Third-Quarter 2025 Dividend",
      "id": 135530402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, June 25, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer.",
      "url": "https://finnhub.io/api/news?id=d0bb0d7eb666335e58628cecff0b54ef6df7349066194cabdb76cadd128ed2e2"
    }
  },
  {
    "ts": null,
    "headline": "Don't Sleep On Pfizer: The Turnaround Is Just Getting Started",
    "summary": "Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.",
    "url": "https://finnhub.io/api/news?id=40d64eec14807cfd7e756f2911823ac70bd1a62395831b54929971747d6d2ae7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750860914,
      "headline": "Don't Sleep On Pfizer: The Turnaround Is Just Getting Started",
      "id": 135527442,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.",
      "url": "https://finnhub.io/api/news?id=40d64eec14807cfd7e756f2911823ac70bd1a62395831b54929971747d6d2ae7"
    }
  },
  {
    "ts": null,
    "headline": "17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars",
    "summary": "Discover the best large-cap stocks for value and dividend safety using YCharts' Value Score and Ben Graham Formula. Click for my exclusive income stock picks.",
    "url": "https://finnhub.io/api/news?id=229d50bad0d84d2de6f84d05a4841e88bc821cb1688b224bf74ea664d7047db3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750860912,
      "headline": "17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars",
      "id": 135527443,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1299294913/image_1299294913.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover the best large-cap stocks for value and dividend safety using YCharts' Value Score and Ben Graham Formula. Click for my exclusive income stock picks.",
      "url": "https://finnhub.io/api/news?id=229d50bad0d84d2de6f84d05a4841e88bc821cb1688b224bf74ea664d7047db3"
    }
  },
  {
    "ts": null,
    "headline": "Will New Drugs Enable BMY to Offset the Impact of Generic Competition?",
    "summary": "BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.",
    "url": "https://finnhub.io/api/news?id=57eb58841c984a3c41f54f6ff2cb7c084852b5aa1ef3fff7d006015493d42d5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750860120,
      "headline": "Will New Drugs Enable BMY to Offset the Impact of Generic Competition?",
      "id": 135526366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.",
      "url": "https://finnhub.io/api/news?id=57eb58841c984a3c41f54f6ff2cb7c084852b5aa1ef3fff7d006015493d42d5f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts",
    "summary": "NEW YORK, June 25, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2025 Performance Report, to be issued that morning.",
    "url": "https://finnhub.io/api/news?id=84d777ed41c475f6ced39cb750d8507a53b8b16c65b2a8053cad2b6982eb7c2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750860000,
      "headline": "Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts",
      "id": 135527874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, June 25, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2025 Performance Report, to be issued that morning.",
      "url": "https://finnhub.io/api/news?id=84d777ed41c475f6ced39cb750d8507a53b8b16c65b2a8053cad2b6982eb7c2f"
    }
  },
  {
    "ts": null,
    "headline": "Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors",
    "summary": "Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to Arbor’s BoardCAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dr. Dolsten most recently served as Chief Scientific Officer and President of Worldwide Research, Development, and",
    "url": "https://finnhub.io/api/news?id=23c90dbc3fc73eb104b760517f5ab10e46382d489e8af6fa4b39cd04626813df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750852800,
      "headline": "Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors",
      "id": 135524342,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to Arbor’s BoardCAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dr. Dolsten most recently served as Chief Scientific Officer and President of Worldwide Research, Development, and",
      "url": "https://finnhub.io/api/news?id=23c90dbc3fc73eb104b760517f5ab10e46382d489e8af6fa4b39cd04626813df"
    }
  },
  {
    "ts": null,
    "headline": "Does Pfizer (NYSE:PFE) Have A Healthy Balance Sheet?",
    "summary": "Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",
    "url": "https://finnhub.io/api/news?id=d75b5b4fc2f16b6020d3e09b05fb297d2b277cd47c641630836f008389141e1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750849216,
      "headline": "Does Pfizer (NYSE:PFE) Have A Healthy Balance Sheet?",
      "id": 135527878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",
      "url": "https://finnhub.io/api/news?id=d75b5b4fc2f16b6020d3e09b05fb297d2b277cd47c641630836f008389141e1f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
    "summary": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
    "url": "https://finnhub.io/api/news?id=a3823b4eab8a3b599bb3f96eadd46ece5ce0a8a1b93cde82204d858cec42fb25",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750843166,
      "headline": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
      "id": 135525019,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a3823b4eab8a3b599bb3f96eadd46ece5ce0a8a1b93cde82204d858cec42fb25"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys",
    "summary": "Explore May 2025 market volatility, U.S.-China trade talks, and record dividend income growth.",
    "url": "https://finnhub.io/api/news?id=28d3b832c1fca31770119594903f09760ded636b8898fcc7533e46ddeeaa3cac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750839000,
      "headline": "My Dividend Stock Portfolio: New May Dividend Record - 100 Holdings With 15 Buys",
      "id": 135524419,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Explore May 2025 market volatility, U.S.-China trade talks, and record dividend income growth.",
      "url": "https://finnhub.io/api/news?id=28d3b832c1fca31770119594903f09760ded636b8898fcc7533e46ddeeaa3cac"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons PFE is Risky and 1 Stock to Buy Instead",
    "summary": "Over the past six months, Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=b758de43cb045e837d80330d376f552f9e3199cd6caf78e4a0fef06445bed901",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750824232,
      "headline": "3 Reasons PFE is Risky and 1 Stock to Buy Instead",
      "id": 135527879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Over the past six months, Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=b758de43cb045e837d80330d376f552f9e3199cd6caf78e4a0fef06445bed901"
    }
  }
]